Navigation Links
CrystalGenomics Completes Phase I MAD Study of its Novel Antibiotic Candidate CG400549, and Prepares for Phase II Clinical Study
Date:5/11/2011

SEOUL, Korea, May 11, 2011 /PRNewswire/ -- CrystalGenomics, Inc., a biopharmaceutical company with 3 clinical stage candidates, has announced today that the draft Clinical Study Report (CSR) from CG400549's Phase I Multiple Ascending Dose (MAD) Study has just been received.

CG400549 is a potential first-in-class antibiotic candidate targeting the fatty acid biosynthesis enzyme FabI, a critical enzyme in generating bacterial membrane and has a novel chemical structure which has never been used as an antibacterial agent previously. CG400549 is being developed to target the notorious resistant bacterial strains such as MRSA (Methicillin Resistant Staphylococcus aureus) and VRSA (Vancomycin Resistant Staphylococcus aureus). CG400549 had successfully completed the Phase I Single Ascending Dose Study in Europe last year and has just received the draft CSR for the Phase I MAD study.

The objective of the MAD study was to evaluate safety, tolerability and pharmacokinetic characteristics of multiple ascending doses of CG400549 in healthy volunteers and a Phase IIa proof-of-concept study is anticipated to initiate as soon as the CSR is finalized.  

CG400549 has displayed remarkable in vitro and in vivo efficacy against some of the gold standard "superbug" therapeutics including Zyvox® and vancomycin as it demonstrated 4 to 8 fold better MICs, respectively. Prior to initiating clinical studies, several in vitro efficacy experiments were conducted at the laboratories of prominent infectious disease clinicians including Dr. Peter Applebaum's lab at the Hershey Medical Center.

Antibacterial resistance is a serious global health issue and one of the main culprits is the infections caused by Staphylococcus aureus such as MRSA. The number of MRSA infections in the United States has been increasing significantly as a 2007 report in Emerging Infectious Diseases, a publication of the
'/>"/>

SOURCE CrystalGenomics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
7. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
8. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
9. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" ... the results of the Company,s 72-patient, placebo-controlled Phase ... for the treatment of dry eye patients using ... model.  The exploratory study was completed in late ... by the Company in a press release, identify ...
(Date:5/22/2015)... Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), a ... its CGuard TM Embolic Prevention System reported positive results ... , at the EuroPCR conference on May 22, ... PARADIGM, an investigator-initiated P rospective evaluation of A ... I n symptomatic and increased-risk asymptomatic carotid artery stenosis, ...
(Date:5/22/2015)... May 22, 2015 Richmond ... research unit with a worldwide reputation for excellence ... frequent publications in peer reviewed medical journals. Its ... and regulators in discussions about rules for transparency ...      (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
(Date:5/23/2015)... Injury lawyer Steven H. Heisler commented today ... the Maryland legislature but which has not been signed to ... HB 449 with overwhelming bipartisan support on April ... into law. This bill ensures that fracking is prohibited in ... the danger of fracking to our water supplies and the ...
(Date:5/22/2015)... San Francisco, CA (PRWEB) May 22, 2015 ... is hosting two exciting events in June. They will ... First Professional Doctorate and a two-day class on Classical ... 1:30-2:30 p.m. June 3, Dr. Steve Given, the Dean ... he will discuss the new First Professional Doctorate program. ...
(Date:5/22/2015)... May 22, 2015 Hundreds of ... behalf of individuals who allegedly experienced serious internal ... continue to move forward in the U.S. District ... Pretrial Order dated May 4, 2015, the Court ... and electronically stored information. Among other things, the ...
(Date:5/22/2015)... May 22, 2015 Combination therapy, ... option for chronic obstructive pulmonary disorder (COPD) as ... and AstraZeneca plc as well as Germany’s Boehringer ... and position. But will market payers, clinicians and ... well-entrenched products to completely new ones? , In ...
(Date:5/22/2015)... May 22, 2015 Family, friends, students, ... world-renowned surgical oncologist, Dr. LaSalle D. Leffall, on Monday, ... luncheon began after Grand Rounds in the hospital’s Tower ... anxiously outside the auditorium, trying to keep the secret. ... if he sees me, he’ll know something is up,” ...
Breaking Medicine News(10 mins):Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:ACTCM Announces Upcoming June Events 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 2Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 3Health News:Court Overseeing Federal Xarelto Lawsuits Establishes Procedures Governing Preservation of Documents, Electronically Stored Information 4Health News:Chronic Obstructive Pulmonary Disorder Therapeutics Market Discussed in In-demand FirstWord Report Published at MarketPublishers.com 2Health News:Colleagues Surprise Dr. LaSalle Leffall with 85th Birthday Celebration 2
... Serves as Network Foundation for the Hospital,s ... State-of-the-Art Cardiothoracic Center, ... announced the completion of a new network,infrastructure to support ... Basildon and Thurrock University Hospitals, part,of the NHS Foundation ...
... will create new dental plan services for members, ... Service (GDS) /,Denex, provider of comprehensive dental plans ... Northwest, a division of the,nation,s leading integrated health ... claims processing, network access and,call center support to ...
... Getting in shape shouldn,t feel like,getting your teeth ... veteran of the fitness industry. For anyone who,s vowed ... a novel fitness,program to help them get going. Recently ... people to "ease into," exercise,going at their own pace, ...
... The chances of infection are boosted 50-fold to 100,000-fold, study ... discovery that perplexes HIV experts, an international team reports that ... of the virus to do its damage. , According to ... , the fibers capture the virus and then ferry it ...
... evolved differently in males and females in order to ... baby, according to research spearheaded at The University of ... for the first time in the Dec. 13 issue ... appeared at least two million years ago, in the ...
... idea on medical and safety grounds , , THURSDAY, ... seven years, a U.S. Food and Drug Administration advisory panel ... drug Mevacor available over the counter. , But with groups ... Union lined up against it, experts think Merck,s proposal is ...
Cached Medicine News:Health News:Extreme Networks Provides Resilient Wired and Wireless Network to the UK's Basildon & Thurrock Hospital 2Health News:Extreme Networks Provides Resilient Wired and Wireless Network to the UK's Basildon & Thurrock Hospital 3Health News:Fitness Guru Offers Novel Exercise Program and Tips to Stick with Exercise in the New Year 2Health News:Fibers in Semen Help HIV Penetrate Cells 2Health News:Adapting to pregnancy played key role in human evolution, study shows 2Health News:FDA Panel Considering Over-the-Counter Statin 2Health News:FDA Panel Considering Over-the-Counter Statin 3Health News:FDA Panel Considering Over-the-Counter Statin 4Health News:FDA Panel Considering Over-the-Counter Statin 5
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: